Conjugated estrogen [horm, phsu, strd]
Equine [mamm]
Combination [qlco]
Progestogens [horm, phsu, strd]
risk factors [qnco]
coronary heart disease [dsyn]
postmenopausal [tmco]
chinese [lang]
Women [popg]
Taiwan [geoa]
randomized [resa]
Study [mnob]
Hormone replacement therapy [topp]
Estrogen [horm, phsu, strd]
Plus [qlco]
Dydrogesterone [horm, phsu, strd]
Estrogen [horm, phsu, strd]
Plus [qlco]
medroxyprogesterone acetate [horm, phsu, strd]
risk factors [qnco]
coronary heart disease [dsyn]
postmenopausal [tmco]
Women [popg]
Methods [inpr]
Randomized Clinical Trial [inpr, resa]
prospective [resa]
Design [acty]
postmenopausal [tmco]
Women [popg]
N NOS [aapp, imft]
Received [qlco]
Sequential [idcn]
Conjugated estrogen [horm, phsu, strd]
Equine [mamm]
Dose [qnco]
mg day [qnco]
days [tmco]
days [tmco]
Women [popg]
Assigned [ftcn]
Receive [qlco]
Dydrogesterone 10 MG [clnd]
Group [idcn]
N NOS [aapp, imft]
medroxyprogesterone acetate 5 MG [clnd]
P group [clna]
N NOS [aapp, imft]
days [tmco]
days [tmco]
Serum Markers [qlco]
Biochemical [ftcn]
Lipoproteins [aapp, bacs]
Plasma [bdsu]
Time, Prothrombin [lbpr]
partial prothrombin time [lbpr]
Antithrombin III Antigen [lbpr]
ATIII [aapp, phsu]
baseline [bodm]
months [tmco]
treatment [ftcn]
Liver function [ortf]
Renal function [ortf]
Plasma [bdsu]
Time, Prothrombin [lbpr]
partial prothrombin time [lbpr]
Trial [resa]
Group [idcn]
High Density Lipoprotein Cholesterol [bacs, lipd]
P group [clna]
months [tmco]
treatment [ftcn]
P NOS [aapp, imft]
Group [idcn]
Reduced concentration [fndg]
Total Cholesterol [lbpr]
Low Density Lipoprotein Cholesterol [bacs, strd]
ATIII [aapp, phsu]
Triglyceride [bacs, lipd]
Increased [qnco]
End [spco]
Trial [resa]
Conclusions [idcn]
Study [mnob]
Favorable [qlco]
Lipoprotein [aapp, bacs]
Profile [lbpr]
Hormone replacement therapy [topp]
regimens [inpr]
Dydrogesterone [horm, phsu, strd]
APPEAR [qlco]
Superior [spco]
medroxyprogesterone acetate [horm, phsu, strd]
Modification [ftcn]
Coronary heart disease risk [inpr]
